A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
B A C K G R O U N D: Treatment for TB is lengthy and toxic, and new regimens are needed. M E T H O D S: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ)...
| الحاوية / القاعدة: | International Journal of Tuberculosis and Lung Disease |
|---|---|
| المؤلف الرئيسي: | |
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
International Union Against Tuberculosis and Lung Disease
2021
|
| الوصول للمادة أونلاين: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103500407&doi=10.5588%2fIJTLD.20.0513&partnerID=40&md5=8c765dc0d897b2fc30f93aff84366e37 |